Emcizumab
The new kid on the block for hemophilia patients.
Key points:
1. This is a bispecific antibody that restores the function of factor 8. It binds to factors 9 and 10, and activates the clotting.
2. Subcutaneous, can be given every 2-4 weeks.
3. Injection site pain, swelling. Risk of clotting in those with previous factor 8 inhibitors.
4. Do not combine with APCC.
No comments:
Post a Comment